FDA Calls for AI Ideas to Turbocharge Drug Testing
Published Date: 4/29/2026
Notice
Summary
The FDA wants your ideas on a new pilot program using AI to make early drug tests faster, safer, and smarter. This could help drug companies and patients by speeding up important decisions without cutting corners on safety. If you have thoughts, send them in by May 29, 2026, and help shape the future of medicine!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
FDA Pilot for AI in Early Trials
If you are a sponsor pursuing early-phase clinical trials (submitting product applications to the FDA Centers CDER, CBER, or the Oncology Center of Excellence), the FDA proposes a pilot program to assess AI-enabled technologies to improve efficiency, speed, and decision-making in early-phase trials. The pilot will recruit such sponsors and be coordinated by the Deputy Chief Medical Officer.
Potential Patient Trial Improvements
The FDA identifies that AI may improve patient recruitment, optimize dose escalation, enhance safety monitoring, enable adaptive trial designs, support earlier Phase 1 to Phase 2 decisions, and improve biomarker assessment and patient selection in early-phase trials. These are areas the pilot will explore to see how AI can affect trial conduct and participant-related processes.
Trustworthy AI Required Principles
The FDA will guide the pilot using principles aligned with the NIST AI Risk Management Framework, including that AI systems be valid, safe, secure, accountable, explainable, privacy-protective, and fair. FDA will apply considerations from its draft guidance on using AI to support regulatory decision-making.
Stakeholder Input Deadline
Stakeholders who want to provide input on the proposed pilot must submit comments by May 29, 2026, via Regulations.gov or by written/paper submission per the docket instructions (Docket No. FDA-2026-N-4390).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-08279 — National Vaccine Injury Compensation Program; List of Petitions Received
The National Vaccine Injury Compensation Program just shared a list of new petitions from people claiming vaccine-related injuries. If you or someone you know got hurt by a vaccine covered by the program, you can file a petition with the Court of Federal Claims to seek compensation—no-fault and fair. Keep an eye on deadlines and rules to make sure your claim counts and you get the money you deserve.
Next: 2026-08282 — Circular Welded Non-Alloy Steel Pipe From Taiwan: Rescission of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce is canceling the review of special steel pipes from Taiwan for the year Nov 2024 to Oct 2025 because no shipments were found to check. This means no extra duties or changes will happen for importers or sellers during this time. The decision kicks in on April 29, 2026, keeping things simple and clear for everyone involved.